Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPC2996 in Relapsed or Refractory CLL
NCT00285103Phase 2Completed
- Sponsor
- Santaris Pharma
- Start
- Jun 2005
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 4
01
Overview
A Phase 2 trial of danvatirsen in chronic lymphocytic leukemia (CLL), sponsored by Santaris Pharma. Started Jun 2005; status: completed.
02
Drugs
danvatirsen
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00285103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00285103.